Clinical Trials Browser

Phase 2 × Carcinoma, Renal Cell × MK 2206 × Clear all

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Phase 2 Terminated

43 enrolled 12 charts

Carcinoma, Renal Cell